Cialis, Levitra market share numbers
Executive Summary
Lilly/Icos' erectile dysfunction therapy Cialis is tracking approximately three percentage points ahead of Bayer/GlaxoSmithKline's Levitra, Lilly said. Lilly reported that for the week ending March 12, Cialis (tadalafil) captured 18.1% of new prescriptions while Levitra (vardenafil) held a 15.4% share. Bayer reported new Rx market share of 16% during its year-end investor meeting March 18 (1"The Pink Sheet" March 22, 2004, p. 27). Both agents are in a head-to-head battle to overtake Pfizer's Viagra, which remains the market leader...
You may also be interested in...
Pfizer Viagra “Value Card” Offers Buy-Six-Get-One-Free Script Deal
Pfizer's Viagra "Value Card" offers patients a free prescription of the erectile dysfunction disorder drug after every six they buy
Bayer/GSK Levitra Has 16% Share Of New Scripts; 2003 Sales Reach $180 Mil.
Bayer/GlaxoSmithKline's Levitra has a 16% share of new prescriptions in the erectile dysfunction disorder market, Bayer CFO Klaus Kuhn reported during a year-end investor meeting March 18
Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: